|
|
Vol. 12.13 – 16 April, 2021
|
|
|
|
|
|
|
|
Researchers discovered that CREB1 played a central role in maintaining new luminal cell survival and that oncogenesis dramatically changed the CREB1-induced transcriptome. CREB1 was active in luminal cells, but not basal cells.
[Oncogene]
|
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
|
The authors showed that photoactivated 3 very efficiently eliminated both prostate bulk, differentiated, and prostate, hardly treatable cancer stem cells simultaneously and with similar efficiency. [Chemistry-A European Journal]
|
|
|
|
|
|
Downregulation of miR-215 was correlated with overexpression of KDM1B in enzalutamide-resistant prostate cancer cells, which promoted AR-dependent AGR2 transcription and regulated the sensitivity to next-generation AR-targeted therapy. [Cancer Gene Therapy]
|
|
|
|
|
|
Scientists measured the effect of the CLK inhibitor, the benzothiazole TG003, on two prostate cancer cell lines. TG003 reduced cell proliferation and increased apoptosis in PC3 and DU145 cells.
[Scientific Reports]
|
|
|
|
|
|
Neuroendocrine prostate cancer (NEPC) diagnosis is challenging as available markers are not sufficiently specific. Investigators identified novel, extracellular vesicles-based biomarkers for diagnosing NEPC. [Scientific Reports]
|
|
|
|
|
|
Using osteoblasts as a model system, scientists observed that prostate cancer cells and their conditioned medium could stimulate and increase mineralization and osteoblasts’ differentiation. [Biology]
|
|
|
|
|
|
Researchers determined which prostate-specific membrane antigen (PSMA)-binding peptide among peptides 563, 562 and 9-mer, showed the highest selectivity towards PSMA using 22Rv1 prostate cancer cells, a cell line with moderate PSMA levels.
[Amino Acids]
|
|
|
|
|
|
Scientists characterized the radiobiological effects induced by Radium-223 and evaluated its kinetics on metastatic prostate cancer cells. [International Journal of Radiation Biology]
|
|
|
|
|
|
|
|
The authors focus on recent progress made in prostate cancer, including the role of protein arginine methyltransferase 5 (PRMT5) in the androgen receptor expression and signaling and DNA damage response, particularly DNA double-strand break repair.
[Cancer Gene Therapy]
|
|
|
|
|
|
|
|
LIDDS AB announced that an application for a new clinical study at Uppsala University Hospital has been submitted. The study will assess intratumoral injections of NZ-DTX Depot, containing the cytotoxic agent docetaxel, in men with prostate cancer who are scheduled for prostatectomy.
[LIDDS AB]
|
|
|
|
|
|
PROCEPT® BioRobotics Corporation announced that Blue Cross Blue Shield of Massachusetts and EmblemHealth are now providing insurance coverage for Aquablation therapy delivered by the AquaBeam® Robotic System for the treatment of benign prostatic hyperplasia
[PROCEPT® BioRobotics Corporation]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Memorial Sloan Kettering – New York, New York, United States
|
|
|
|
|
|
|
The University of Texas MD Anderson Cancer Center – Houston, Texas, United States
|
|
|
|
|
|
|
Virginia Commonwealth University – Richmond, Virginia, United States
|
|
|
|
|
|
|
University of Calgary – Calgary, Alberta, Canada
|
|
|
|
|
|
|
Duke University – Durham, North Carolina, United States
|
|
|
|
|
|